Literature DB >> 11268233

Adverse drug effects, compliance, and initial doses of antihypertensive drugs recommended by the Joint National Committee vs the Physicians' Desk Reference.

J S Cohen1.   

Abstract

BACKGROUND: Compliance problems are common causes of the inadequate treatment of hypertension, with 16% to 50% of patients quitting treatment within 1 year. Dose-related adverse drug events (ADEs) frequently cause compliance problems, and many ADEs occur with the initial doses of antihypertensive drugs. Thus, it is an established tenet to initiate antihypertensive therapy at low doses to avoid ADEs that diminish patients' quality of life and reduce compliance. However, what are the lowest effective doses of antihypertensive drugs?
OBJECTIVE: To compare the initial doses recommended in the Physicians' Desk Reference (PDR) with those recommended by the Sixth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI).
METHODS: Review of the latest JNC VI report (1997) and the 1999 and 2000 editions of the PDR and the medical literature.
RESULTS: The JNC VI recommends substantially lower initial doses for 23 (58%) of 40 drugs, compared with the PDR. In addition, for 37 (82%) of 45 drugs, PDR guidelines do not suggest lower initial doses for old or frail patients than for younger adults.
CONCLUSIONS: Although the PDR is the drug reference most used by physicians, it does not reflect the lowest initial doses that are recommended by the JNC VI for many of the most prescribed antihypertensive drugs. Because avoidance of ADEs is essential to maintaining compliance with antihypertensive therapy, and because many antihypertensive ADEs are dose related, physicians must know the very lowest, effective, least ADE-prone doses. Patients and physicians would benefit by establishing mechanisms to make this information readily available to all practicing physicians.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11268233     DOI: 10.1001/archinte.161.6.880

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  17 in total

1.  Off-label prescribing in oncology.

Authors:  Susan G Poole; Michael J Dooley
Journal:  Support Care Cancer       Date:  2004-02-18       Impact factor: 3.603

2.  TRPV1 (Transient Receptor Potential Vanilloid 1) Cardiac Spinal Afferents Contribute to Hypertension in Spontaneous Hypertensive Rat.

Authors:  Julia Shanks; Sharon D B de Morais; Lie Gao; Irving H Zucker; Han-Jun Wang
Journal:  Hypertension       Date:  2019-08-19       Impact factor: 10.190

3.  Worldwide analysis of factors associated with medicines compendia publishing.

Authors:  Blanca Arguello; Fernando Fernandez-Llimos
Journal:  Int J Clin Pharm       Date:  2013-03-28

4.  Actual practice in hypertension: implications for persistence with and effectiveness of therapy.

Authors:  J D Spence; T C Hurley; J D Spence
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

Review 5.  The Pharmacogenomic and Metabolomic Predictors of ACE Inhibitor and Angiotensin II Receptor Blocker Effectiveness and Safety.

Authors:  Hania K Flaten; Andrew A Monte
Journal:  Cardiovasc Drugs Ther       Date:  2017-08       Impact factor: 3.727

6.  Compliance with therapy in hypertensive patients.

Authors:  Alfonso Lagi; Antonio Rossi; Maria Teresa Passaleva; Alessandro Cartei; Simone Cencetti
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

Review 7.  Effect of antihypertensive agents on quality of life in the elderly.

Authors:  Roberto Fogari; Annalisa Zoppi
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

8.  Quinapril for treatment of hypertension in Turkey: dose titration and diuretic combination treatment strategies.

Authors:  Gul Yener; Sinan Aran; Mithat Bahceci; Kurtulus Ozdemir; Fusun Gultekin; Wing Lowe
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

9.  Adverse events of blood-pressure-lowering drugs: evidence of high incidence in a clinical setting.

Authors:  Carla B C Gonçalves; Leila B Moreira; Miguel Gus; Flávio D Fuchs
Journal:  Eur J Clin Pharmacol       Date:  2007-08-11       Impact factor: 2.953

Review 10.  The economic impact of hypertension.

Authors:  William J Elliott
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 May-Jun       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.